Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
By Kelly Cloonan
Gilead Sciences plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion.
Under the terms of the deal, Gilead would buy all of the outstanding equity of Ouro for about $1.68 billion in cash upfront, which is payable at closing, and up to $500 million in contingent milestone payments.
Gilead said the deal would bolster its growing inflammation portfolio, adding gamgertamig, which has demonstrated efficacy after a single treatment cycle in severe antibody-mediated orphan diseases including autoimmune hemolytic anemia and immune thrombocytopenia in continuing Phase 1/2 clinical studies.
Gamgertamig was granted Fast Track and Orphan Drug Designation by the Food and Drug Administration for the treatment of both diseases, and is expected to enter registrational studies in 2027, Gilead said.
"This acquisition underscores our commitment to advancing transformative therapies for people living with serious autoimmune diseases," Gilead Chief Medical Officer Dietmar Berger said.
Gilead also said it is in talks with Galapagos for a potential research-and-development collaboration for the assets it plans to purchase from Ouro.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 23, 2026 18:55 ET (22:55 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States